Estrella Immunopharma S.A.

ESLA

Chart

Market data via TradingView · delayed

Latest report

Published Sep 9, 2026

Estrella Immunopharma (ESLA): A Sub Scale T Cell Program Tethered to Its Parent

In-depth research on ESLA covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.

3,772 words17 min read
Read report